Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
So what: In the third quarter, revenue grew 27% to $11.7 million and the net loss reached $22.7 million, or $0.30 per share. The loss was partly because of litigation expenses, of which $7 million was a non-cash charge.
Now what: Sequenom, a genomic sciences company, said capital reserves would be enough to fund operations through mid-2011, but I'm wondering how long it can make it after that. Wide losses are predicted through 2011, forcing me to stay away from this speculative company. I'll sit out until I see a solid profit and a quarter when the company doesn't miss expectations.
Interested in more info on Sequenom? Add it to your watchlist by clicking here.